MM patients in England & Wales who have recently had SCT, or do so in the future, should now be offered low dose lenalidomide maintenance. At long last today it was announced that NICE & NHS have reached a financial agreement with the pharmaceutical company so patients can benefit from this highly successful treatment. I am so relieved, even though it won’t help us who went through SCT some time ago.
